Home » Topics » Dermatologic, BioWorld Science

Dermatologic, BioWorld Science
RSS

Topline results from two pivotal phase III trials of SB-204 in patients with acne vulgaris

Jan. 30, 2017

Merck KGaA reports findings from phase Ib study of M-1095 in psoriasis

Jan. 26, 2017

FDA approves Rhofade, Allergan's topical treatment for persistent facial erythema

Jan. 20, 2017

FDA awards rare pediatric disease designation to TXA-127 from Tarix Orphan

Jan. 19, 2017

Promising results from final phase III trial of Cimzia in chronic plaque psoriasis

Jan. 19, 2017

Novel TyroSphere formulation of adapalene for topical acne therapy

Jan. 19, 2017

Sato Pharmaceutical obtains rights to SB-204 in Japan

Jan. 18, 2017

Valeant reports positive results from second phase III study of psoriasis drug

Jan. 11, 2017

FDA grants fast track status to FCX-007 from Fibrocell Science

Jan. 9, 2017

Dermira doses first patient in phase III acne study

Jan. 5, 2017

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
NRF2 activators reported in Vailima Peninsula patent
BioWorld Science
Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of...